ENDRA Life Sciences Inc. Common Stock (NDRA) is a publicly traded Healthcare sector company. As of October 1, 2026, NDRA trades at $5.67 with a market cap of $8.94M and a P/E ratio of -0.66. NDRA moved -0.67% today. Year to date, NDRA is +37.06%; over the trailing twelve months it is +4.66%. Its 52-week range spans $2.90 to $11.96. Rallies surfaces NDRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ENDRA Life Sciences enters first amendment to merger agreement on October 1, 2026: ENDRA Life Sciences entered a first amendment to its merger agreement on October 1, 2026; its filing also said Renergen’s borrowing capacity from ASPI increased to $120 million and is to increase to $200 million.
| Metric | Value |
|---|---|
| Price | $5.67 |
| Market Cap | $8.94M |
| P/E Ratio | -0.66 |
| EPS | $-8.93 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.96 |
| 52-Week Low | $2.90 |
| Volume | 23.23K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-7.03M |
| Gross Margin | 0.00% |
NDRA analyst coverage data. Average price target: $0.00.